Aveo could lose Fotivda's EU approval if August analysis confirms negative OS trend

EMA's CHMP will consider regulatory action should an interim overall survival analysis of Fotivda tivozanib, planned for August, confirms the negative OS

Read the full 221 word article

How to gain access

Continue reading with a
two-week free trial.